Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Organon (OGN) has seen a recent price increase of 14.8% over the past month, outpacing the S&P 500 and its industry. While the current quarter's earnings are projected to decline 18.8% year-over-year to $0.91 per share, and fiscal year 2024 earnings are expected to decrease 7.3% to $3.81, fiscal year 2025 is forecasted to grow 4.8% to $4.00. Despite mixed revenue projections and a Zacks Rank #3 (Hold), Organon's 'A' grade in Zacks Value Style Score suggests it is currently undervalued relative to its peers.

Analysis

Organon & Co. (OGN) has demonstrated significant recent stock price appreciation, with a +14.8% return over the past month, substantially outperforming both the S&P 500 composite's +3.6% and its Zacks Medical Services industry's +3.8% gain. Despite this momentum, the company faces near-term fundamental headwinds. Earnings for the current quarter are projected at $0.91 per share, a decline of -18.8% year-over-year, and the current fiscal year's consensus EPS of $3.81 indicates a -7.3% decrease from the prior year. Revenue forecasts echo this trend, with an expected -3.4% year-over-year decline to $1.55 billion for the current quarter and a -2.5% fall to $6.24 billion for the current fiscal year. However, analysts anticipate a recovery in the next fiscal year, with consensus EPS projected to grow +4.8% to $4.00 and revenues to see a slight uptick of +0.2% to $6.25 billion; these estimates have remained unchanged over the last 30 days. In its last reported quarter, Organon's revenues of $1.51 billion (-6.7% YoY) missed consensus by -0.73%, but EPS of $1.02 significantly beat expectations by +14.61%, continuing a pattern of beating EPS estimates for four consecutive quarters. The stock currently holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the market, yet it scores an 'A' on the Zacks Value Style Score, indicating it is trading at a discount relative to its peers.

Key Decisions for Investors

• Investors should consider the current undervaluation indicated by the 'A' Zacks Value Style Score in light of the stock's recent +14.8% monthly outperformance, but remain cognizant of projected near-term earnings declines (-18.8% current quarter, -7.3% current fiscal year) and revenue contraction (-3.4% current quarter, -2.5% current fiscal year).
• The Zacks Rank #3 (Hold) suggests a neutral stance may be warranted; however, close monitoring of upcoming earnings is crucial to validate the anticipated EPS growth of +4.8% and modest revenue recovery (+0.2%) for the next fiscal year, which could serve as a key catalyst.
• Particular attention should be paid to whether Organon can maintain its consistent EPS surprise history, as seen in the last four quarters, and if revenue performance begins to align with or exceed the muted growth expectations for the next fiscal year.